{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000111","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.379889+00:00","generated_at":"2026-06-06T10:39:45.028660+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alaunos Therapeutics effects 1-for-15 reverse stock split effective Jan 31, 2024","bullets":["Reverse stock split at a ratio of 1-for-15, effective January 31, 2024 at 5:00 p.m. ET.","Every 15 pre-split shares converted into 1 share; par value unchanged at $0.001.","Common stock continues trading on Nasdaq under symbol TCRT; new CUSIP 98973P200.","Split ratio chosen by Board on Jan 12, 2024; stockholder authority granted at June 6, 2023 annual meeting.","Equiniti Trust Company appointed as exchange agent for processing share conversions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000111","json":"https://secwatch.observer/filing/0001193805-24-000111.json","markdown":"https://secwatch.observer/filing/0001193805-24-000111.md","text":"https://secwatch.observer/filing/0001193805-24-000111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119380524000111/0001193805-24-000111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119380524000111/e619211_8k-at.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:39:45.028660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"341a946bb47c3f51d0991cb4118a83b1b19983da","claim":"Alaunos Therapeutics, Inc.: Filed a Second Amended and Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split (effective 2024-01-31).","evidence_excerpt":"On January 31, 2024, Alaunos Therapeutics, Inc. (the “Company”) filed a Second Amended and Restated Certificate of Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company’s common stock at a ratio of 1-for-15 (the “Reverse Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119380524000111/0001193805-24-000111-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-01-31"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}